Source: Annual Congress 2006 - Recent advances in the treatment of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Rennard, T. Bantje, M. Higgins, D. Jack, R. Owen (Omaha, United States Of America; Breda, Netherlands; Horsham, United Kingdom). Indacaterol, a novel once-daily β₂-agonist, provides effective 24-hour bronchodilation in moderate-to-severe COPD. Eur Respir J 2006; 28: Suppl. 50, 3053

Member's Comments

No comment yet.

Related content which might interest you: NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006 Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009 Indacaterol, a novel once-daily β2-agonist, is well tolerated in persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 204s Year: 2006 Indacaterol once-daily provides significant bronchodilation irrespective of baseline reversibility in COPD patients Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 Indacaterol, a novel 24-hour β2-agonist, is effective and well tolerated on multiple dosing in patients with mild to moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 287s Year: 2005 Single-dose indacaterol, a novel 24-hour β2-agonist, is well tolerated in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005 Indacaterol provides effective bronchodilation in patients with COPD regardless of concomitant ICS use Source: Annual Congress 2010 - Bronchodilators in airways disease Year: 2010 NVA237 once daily provides rapid, clinically meaningful and sustained 24-h bronchodilation in patients with COPD: The GLOW1 trial Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Indacaterol: the first once-daily β2-agonist with 24-hour bronchodilation Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005 Cardiac safety of indacaterol, a novel once-daily bronchodilator, in COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Indacaterol provides effective bronchodilation in patients with COPD irrespective of age Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 Cardiac safety of indacaterol, a novel once-daily bronchodilator, in asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthma Source: Eur Respir J 2007; 29: 871-878 Year: 2007 Dual bronchodilation with QVA149 and the free combination of indacaterol and glycopyrronium are equally safe and well tolerated in patients with COPD: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Safety of multiple-dose indacaterol, a novel 24-hour β2-agonist, in moderate to severe COPD Source: Eur Respir J 2005; 26: Suppl. 49, 295s Year: 2005 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol Source: Annual Congress 2008 - New treatments for asthma Year: 2008 Qva149, a novel combination of indacaterol and glycopyrronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Once-daily budesonide/formoterol via a single inhaler is effective in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008